| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2025 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 62,250 | $16.06 | $999,424.86 | -82.8% | +10.0% | +109.8% | |
| Mar 4, 2025 | TEVA Teva Pharmaceutical Industries Ltd | Francis Richard D | President And CEO | Sell | 31,342 | $16.06 | $503,235.99 | -5.9% | +10.0% | +109.8% | |
| Mar 4, 2025 | TEVA Teva Pharmaceutical Industries Ltd | Hughes Eric A | See "remarks" | Sell | 24,900 | $16.06 | $399,770.20 | -82.8% | +10.0% | +109.8% | |
| Mar 4, 2025 | GTBIF Green Thumb Industries Inc. | Kravitz Bret | General Counsel And Secretary | Sell | 7,748 | $6.68 | $51,789.18 | -1.2% | - | - | |
| Mar 4, 2025 | PFE Pfizer Inc | Damico Jennifer B.58 | SVP &Controller | Sell | 2,500 | $25.93 | $64,825.00 | -17.4% | -8.9% | +3.4% | |
| Mar 3, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 220,000 | $928.76 | $204,326,150.89 | - | -19.6% | +8.4% | |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Patel Gautam | Director | Sell | 80,000 | $8.90 | $712,000.00 | -4.2% | -15.3% | +52.1% | |
| Mar 3, 2025 | AKBA Akebia Therapeutics, Inc. | Butler John P.61 | CEO And President | Sell | 46,409 | $1.83 | $84,928.47 | -1.8% | +80.6% | -32.5% | |
| Mar 3, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Klee Justin B.60 | Co-chief Executive Officer | Sell | 4,595 | $3.15 | $14,483.44 | -0.1% | +70.0% | +370.3% | |
| Mar 3, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Cohen Joshua B60 | Co-chief Executive Officer | Sell | 4,595 | $3.17 | $14,549.15 | -0.1% | +70.0% | +370.3% | |
| Mar 3, 2025 | PBH Prestige Consumer Healthcare Inc. | Fritz Mary Beth57 | SVP Quality &Regulatory | Sell | 6,297 | $85.39 | $537,700.83 | -25.1% | +0.3% | -19.1% | |
| Mar 3, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Mazzariello Gina53 | Chief Legal Officer | Sell | 1,611 | $3.12 | $5,022.29 | -1.2% | +70.0% | +370.3% | |
| Mar 3, 2025 | UTHR United Therapeutics Corp | Benkowitz Michael47 | President And COO | Sell | 9,679 | $311.99 | $3,019,735.65 | -27.0% | +5.0% | +60.8% | |
| Mar 3, 2025 | HIMS Hims & Hers Health, Inc. | Becklund Irene | Pao | Sell | 2,913 | $45.14 | $131,492.82 | -39.8% | +39.6% | -61.1% | |
| Mar 3, 2025 | AKBA Akebia Therapeutics, Inc. | Burke Steven Keith61 | SVP, Chief Medical Officer | Sell | 7,144 | $1.83 | $13,073.52 | -0.9% | +80.6% | -32.5% | |
| Mar 3, 2025 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | Director | Sell | 53,107 | $94.35 | $5,010,733.79 | -2.2% | -18.7% | -16.9% | |
| Mar 3, 2025 | LQDA Liquidia Corp | Adair Jason | Chief Business Officer | Sell | 451 | $15.45 | $6,967.95 | -0.2% | +13.4% | +113.7% | |
| Mar 3, 2025 | LQDA Liquidia Corp | Kaseta Michael57 | CFO And COO | Sell | 874 | $15.45 | $13,503.30 | -0.2% | +13.4% | +113.7% | |
| Mar 3, 2025 | LQDA Liquidia Corp | Schundler Russell58 | General Counsel | Sell | 930 | $15.45 | $14,368.50 | -0.2% | +13.4% | +113.7% | |
| Mar 3, 2025 | LQDA Liquidia Corp | Moomaw Scott | Chief Commercial Officer | Sell | 592 | $15.45 | $9,146.40 | -0.3% | +13.4% | +113.7% | |
| Feb 28, 2025 | HROW Harrow, Inc. | Opaleye Management Inc.60 | 10% Owner | Sell | 5,000 | $28.05 | $140,250.00 | -3.2% | -3.1% | +92.9% | |
| Feb 28, 2025 | UTHR United Therapeutics Corp | Kurzweil Ray | Director | Sell | 15,000 | $317.01 | $4,755,151.44 | -9.3% | +0.1% | +57.4% | |
| Feb 28, 2025 | TEVA Teva Pharmaceutical Industries Ltd | Kalif Eliyahu Sharon | EVP, Chief Financial Officer | Sell | 55,750 | $16.21 | $903,462.20 | -27.4% | +6.5% | +105.7% | |
| Feb 28, 2025 | AYTU Aytu Biopharma, Inc | Disbrow Joshua R.57 | Chief Executive Officer | Buy | 15,000 | $1.30 | $19,500.00 | +21.0% | +41.9% | +99.2% | |
| Feb 28, 2025 | UTHR United Therapeutics Corp | Thompson Tommy G51 | Director | Sell | 2,500 | $318.34 | $795,837.75 | -22.8% | +0.1% | +57.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.